Abstracts tagged "neuropsychiatric disorders and systemic lupus erythematosus (SLE)"

Abstract Number: 709 • 2018 ACR/ARHP Annual Meeting
Differential Characteristics of Lupus Psychosis and Steroid Psychosis
Shunsei Hirohata^1,2,3, Yoshinori Kanai⁴, Akiko Mitsuo⁵, Yoshiaki Tokano⁴ and Hiroshi Hashimoto⁴, ¹Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Nobuhira Hospital, Tatsuno, Japan, ³Kitasato University School of Medicine, Sagamihara, Japan, ⁴Juntendo University School of Medicine, Tokyo, Japan, ⁵Rheumatology, National Hospital Organization Disaster Medical Center, Tokyo, Japan
Background/Purpose: Psychiatric manifestations are relatively common in patients with systemic lupus erythematosus (SLE). Since there are a number of factors causing psychiatric manifestations other than…
Abstract Number: 731 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Neurophysiological Patterns of Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience
Francisco Treviño-Tello¹, Erwin Chiquete², Christopher Cabib², Ariadna Díaz-Mora¹, Mariana Lopez-Lopez¹, Ivonne Sandoval-Flores¹, Juan José Gómez-Piña² and Hilda Fragoso-Loyo¹, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Neurology and Neuropsychiatry, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: The prevalence of peripheral neurological manifestations in Systemic Lupus Erythematosus (SLE) ranges between 5% and 27% and are a major cause of morbidity. The…
Abstract Number: 691 • 2017 ACR/ARHP Annual Meeting
Serum Anti-NR2 Has a Better Specificity Than Sensitivity in Diagnosing Neuropsychiatric Systemic Lupus Erythematosus (NPSLE)
Seyed-Foad Ahmadi¹, Golara Zahmatkesh², Masoud Majed³ and Sheetal Desai⁴, ¹Department of Medicine, University of California Irvine, Orange, CA, ²Department of Psychiatry, Charles Drew University of Medicine and Science/UCLA, Los Angeles, CA, ³Division of Neuroimmunology, Mayo Clinic, Rochester, MN, ⁴Medicine/Rheumatology, Unviersity of California, Irvine, Orange, CA
Background/Purpose: Anti-NR2, a subclass of anti-NMDA receptor antibodies, is reportedly associated with NPSLE syndromes. However, its diagnostic accuracy is inconsistent across prior studies. Hence, we…
Abstract Number: 717 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Neuropsychiatric Systemic Lupus Erythematosus and Its Recurrence
Ryusuke Anan, Yuko Kaneko, Jun Kikuchi and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Neuropsychiatric involvement in systemic lupus erythematosus (NPSLE) is the leading cause of morbidity and mortality in patients with SLE but not well understood. The…
Abstract Number: 900 • 2017 ACR/ARHP Annual Meeting
Choroid Plexus Tertiary Lymphoid Structures in Lupus: A Novel Neuro-Immune Interface
Ariel Stock¹, Evan Der², Sivan Gelb³, Ayal Ben-Zvi³ and Chaim Putterman⁴, ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Hebrew University, Jerusalem, Israel, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: The central nervous system (CNS) manifestations of SLE remain poorly understood. Although potentially neuropathic autoantibodies have been identified in the serum, lupus patients show…
Abstract Number: 2649 • 2017 ACR/ARHP Annual Meeting
Anti-Suprabasin Antibody; A Novel Autoantibody May Contribute to the Pathogenesis of Neuropsychiatric Systemic Lupus Erythematosus
Kunihiro Ichinose¹, Kaname Ohyama², Kaori Furukawa¹, Osamu Higuchi³, Shunya Nakane⁴, Masataka Umeda¹, Tomohiro Koga¹, Takashi Igawa¹ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Course of Pharmaceutical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Clinical Research, Nagasaki Kawatana Medical Center, Nagasaki, Japan, ⁴Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Background/Purpose: Systemic lupus erythematosus (SLE), an autoimmune disorder characterized by the production of pathogenic autoantibodies and inflammatory mediators, involves multiple organ systems. Neuropsychiatric systemic lupus…
Abstract Number: 2826 • 2016 ACR/ARHP Annual Meeting
Clinical Utility of Circulating Anti-N-Methyl-D-Aspartate Receptor Subunits NR2A/B Antibody for the Diagnosis of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Sjogren’s Syndrome: An Updated Meta-Analysis
Sen Hee Tay¹, Anna-Marie Fairhurst² and Anselm Mak¹, ¹Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, Singapore, ²Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore
Background/Purpose: Neuropsychiatric (NP) events are found in patients with rheumatic diseases, commonly in systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). The standard nomenclature and…
Abstract Number: 2856 • 2016 ACR/ARHP Annual Meeting
Serum C5a Is Elevated in Lupus Nephritis and in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms
Yuko Sakuma¹, Tatsuo Nagai², Taku Yoshio³ and Shunsei Hirohata⁴, ¹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ³Jichi Medical University, Tochigi, Japan, ⁴Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown…
Abstract Number: 1773 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Cerebrovascular Events in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
John G Hanly¹, Qiuju Li², Li Su³, Murray Urowitz⁴, Juanita Romero-Diaz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Sasha Bernatsky⁸, Ann E. Clarke⁹, Daniel J Wallace¹⁰, Joan T. Merrill¹¹, David A. Isenberg¹², Anisur Rahman¹³, Ellen M. Ginzler¹⁴, Paul R. Fortin¹⁵, D Gladman¹⁶, Jorge Sanchez-Guerrero¹⁷, Michelle Petri¹⁸, Ian N. Bruce¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Cynthia Aranow²², Graciela S. Alarcon²³, Kristján Steinsson²⁴, Gunnar K. Sturfelt²⁵, Ola Nived²⁶, Susan Manzi²⁷, M Khamashta²⁸, Ronald F. van Vollenhoven²⁹, Asad Zoma³⁰, Guillermo Ruiz-Irastorza³¹, S. Sam Lim³², Murat Inanc³³, Kenneth C. Kalunian³⁴, Diane L. Kamen³⁵, Christine A. Peschken³⁶, Søren Jacobsen³⁷, Anca Askanase³⁸, Chris Theriault³⁹, Vernon Farewell⁴⁰ and Manuel Ramos-Casals⁴¹, ¹Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ²MRC Biostatistics Unit, Cambridge, United Kingdom, ³Nova Scotia Rehab Site, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁶NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of, ⁸Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁰Cedars-Sinai Medical Center, West Hollywood, CA, ¹¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹³Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁴Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ¹⁵Rheumatology, University of Laval, Quebec, QC, Canada, ¹⁶University of Toronto, Toronto, ON, Canada, ¹⁷Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ¹⁸Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ²⁰Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²¹FSM, Northwestern University, Chicago, IL, ²²Molecular Medicine and Medicine, Hofstra Northwell School of Medicine, Hempstead, NY, ²³Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²⁴Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁵Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ²⁶Department of Rheumatology, University Hospital, Lund, Sweden, ²⁷Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ²⁸Lupus Research Unit, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²⁹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³⁰Rheumatology, Hairmyres Hospital, East Kilbride, Great Britain, ³¹Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ³²Medicine, Emory University School of Medicine, Atlanta, GA, ³³Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁴Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³⁶RR 149G, Univ of Manitoba, Winnipeg, MB, Canada, ³⁷Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁸Rheumatology, Columbia University Medical Center, New York, NY, ³⁹Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴⁰Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴¹Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Neuropsychiatric (NP) disease in patients with SLE includes cerebrovascular events (CerVE). We determined the frequency, attribution and risk factors for CerVE in a large,…
Abstract Number: 1781 • 2016 ACR/ARHP Annual Meeting
Analysis of Influences of Various Factors on the Prognosis of Acute Confusional State of Diffuse Psychiatric/Neuropsychological Syndromes in Systemic Lupus Erythematosus
Gakuro Abe¹, Yoshiyuki Arinuma¹, Hirotoshi Kikuchi² and Shunsei Hirohata¹, ¹Kitasato University School of Medicine, Sagamihara, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE), especially diffuse psychiatric/neuropsychological syndromes (diffuse NPSLE), is one of the most difficult complications of the disease. For the evaluation…
Abstract Number: 2808 • 2016 ACR/ARHP Annual Meeting
Role of Serum Autoantibodies in Blood Brain Barrier Damages in Neuropsychiatric Systemic Lupus Erythematosus
Shunsei Hirohata¹, Yuko Sakuma², Tamiko Yanagida³ and Taku Yoshio⁴, ¹Kitasato University School of Medicine, Sagamihara, Japan, ²Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ³Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁴Jichi Medical University, Tochigi, Japan
Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown…
Abstract Number: 2819 • 2016 ACR/ARHP Annual Meeting
Clinical Utility of Anti-Aquaporin 4 Antibody Measurement in Patients with Neuropsychiatric Systemic Lupus Erythematosus with Neuromyelitis Optica Spectrum Disorder Manifestations
Simone Mader¹, Yoshiyuki Arinuma¹, Venkatesh Jeganathan¹, Yuichiro Fujieda², Irena Dujmovi³, Jelen Drulovic³, Yuko Sakuma⁴, Shinsuke Yasuda⁵, Joel Stern⁶, Cynthia Aranow⁶, Meggan Mackay⁷, Tatsuya Atsumi⁵, Shunsei Hirohata⁸ and Betty Diamond⁹, ¹Center of Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ²Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Clinical Centre of Serbia University School of Medicine, Belgrade, Serbia, ⁴Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁵Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁶The Feinstein Institute for Medical Research, Manhasset, NY, ⁷Autoimmune & Musculoskeletal Disorders, The Feinstein Institute for Medical Research, Manhasset, NY, ⁸Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁹Autoimmune & Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease characterized by the presence of autoantibodies. Among the complications of SLE, neuropsychiatric manifestations (NPSLE) can…
Abstract Number: 387 • 2015 ACR/ARHP Annual Meeting
Features of 847 Childhood-Onset Systemic Lupus Erythematousus Patients in Three Age-Related Groups at Diagnosis: A Brazilian Multicenter Study
Clovis A Silva¹, Roberta C. Gomes Sr.², Marco F. Silva³, Katia T. Kozu⁴, Eloisa Bonfá⁵, Rosa M R Pereira⁶, Maria Teresa Terreri⁷, Claudia S. Magalhães Sr.⁸, Silvana B. Sacchetti Sr.⁹, Roberto Marini Sr.¹⁰, Melissa Fraga¹¹, Luciana M. Carvalho Sr.¹², Cássia M. Barbosa¹³ and Magda Carneiro-Sampaio Sr.¹⁴, ¹Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit-Children’s Institute,, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Pediatrics, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁵Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁶Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁷Pediatrics, Universidade Federal de Sao Paulo, São Paulo, Brazil, ⁸Pediatric Rheumatology Unit, São Paulo State University – Faculdade de Medicina de Botucatu, São Paulo, Brazil, ⁹Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ¹⁰Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, ¹¹Pediatrics, Universidade Federal de São Paulo / UNIFESP, São Paulo, Brazil, ¹²Pediatric Rheumatology Unit, Ribeirão Preto Medical School – University of São Paulo, São Paulo, Brazil, ¹³Pediatric Rheumatology Unit, Hospital Infantil Darcy Vargas, São Paulo, Brazil, ¹⁴Pediatric Allergology and Immunology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Previous retrospective evaluations suggested that age at diagnosis may influence disease expression in terms of initial clinical presentation, pattern of organ involvement and serological…
Abstract Number: 761 • 2015 ACR/ARHP Annual Meeting
Neurometabolic Alterations in Korean Lupus Patients with Chronic Daily Headache
Ji-Min Kim¹, Tae-Han Lee¹, Chang-Nam Son¹, Sung Soo Kim², Hyuk Won Chang³ and Sang-Hyon Kim¹, ¹Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Ulsan University School of Medicine, GangNeung Asan Hospital, Gangneung, South Korea, ³Department of Radiology, Keimyung University School of Medicine, Daegu, South Korea
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (SLE) includes a broad spectrum of neurologic and psychiatric manifestations. One of the most commonly observed neuopsychiatric symptoms is headache.…
Abstract Number: 2951 • 2015 ACR/ARHP Annual Meeting
Anti-NR2 Antibody and Blood-Brain Barrier Disruption in Systemic Lupus Erythematosus Patients with Cognitive Dysfunction
Gaurav Gulati¹, Philip Iffland², Damir Janigro², Bin Zhang³ and Michael Luggen⁴, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ³Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁴Division of Immunology, University of Cincinnati Medical Center, Cincinnati, OH
Background/Purpose: Cognitive Dysfunction (CD) is one of the most common manifestations of neuropsychiatric SLE (NPSLE) and one of the most devastating. The pathogenesis of CD…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].